CDK2 and cancer: In addition to RNAi, small molecule inhibitors like Adavosertib, a WEE1 inhibitor, have been explored for their ability to inhibit cyclin E/CDK2 complexes, slowing down cell cycle progression in cancers with CCNE1 amplification [46].